Evaluation of tuberculosis control policies using computer simulation

JAMA

Volumn 276, Issue 23, 1996, Pages 1898-1903

  Brewer, Timothy F ^a,b,f   Heymann, S Jody ^b,c,d   Colditz, Graham A ^a,b,d   Wilson, Mary E ^b,d,e   Auerbach, Kenneth ^d   Kane, David ^c   Fineberg, Harvey V ^d  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c HARVARD UNIVERSITY   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^e MOUNT AUBURN HOSPITAL   (United States)

^f CHANNING LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; TUBERCULIN; TUBERCULOSTATIC AGENT;

ADOLESCENT; ADULT; ARTICLE; BCG VACCINATION; CHILD; COMPUTER SIMULATION; HEALTH CARE POLICY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; TUBERCULIN TEST; TUBERCULOSIS; TUBERCULOSIS CONTROL; UNITED STATES;

EID: 0029856187     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.276.23.1898     Document Type: Article

References (70)

1. Rieder HL, Cauthen GM, Comstock GW, Snider DE. Epidemiology of tuberculosis in the United States. Epidemiol Rev. 1989;11:79-98.
2. Centers for Disease Control and Prevention. Expanded tuberculosis surveillance and tuberculosis morbidity - United States, 1993. MMWA Morb Mortal Wkly Rep. 1994;43:361-366.
3. Bloch AB, Cauthen GM, Onorato IM, et al. Nationwide survey of drug-resistant tuberculosis in the United States. JAMA. 1994;271:665-671.
4. Frieden TR, Sterling T, Pablos-Mendez A, et al. The emergence of drug-resistant tuberculosis in New York City. N Engl J Med. 1993;328:521-526.
5. Centers for Disease Control and Prevention. Tuberculosis morbidity - United States, 1994. MMWR Morb Morial Wkly Rep. 1995;44:387-389, 395.
6. Hamburg MA. The challenge of controlling tuberculosis in New York City. N Y State J Med. 1992;92:291-293.
7. Gutman L, Moye J, Zimmer B, Tian C. Tuberculosis in human immunodeficiency virus-exposed or-infected United States children. Pediatr Infect Dis J. 1994;13:963-968.
8. Brown RE, Miller B, Taylor WR, et al. Healthcare expenditures for tuberculosis in the United States. Arch Intern Med. 1995;155:1595-1600.
9. McKenna MT, McCray E, Onorato I. The epidemiology of tuberculosis among foreign-born persons in the United States, 1986 to 1993. N Engl J Med. 1995;332:1071-1076.
10. Brudney K, Dobkin J. Resurgent tuberculosis in New York City. Am Rev Respir Dis. 1991;144: 745-749.
11. Centers for Disease Control. National action plan to combat multidrug-resistant tuberculosis. MMWR Morb Mortal Wkly Rep. 1992;41(suppl RR-11):1-45.
12. Centers for Disease Control. Prevention and control of tuberculosis in U.S. communities with at-risk minority populations and prevention and control of tuberculosis among homeless persons. MMWR Morb Mortal Wkly Rep. 1992;41(suppl RR-5):1-23.
13. Centers for Disease Control. Prevention of tuberculosis in migrant farm workers. MMWR Morb Mortal Wkly Rep. 1992;41(suppl RR-10):1-11.
14. Rouillon A, Waaler H. BCG vaccination and epidemiological situation: a decision making approach to the use of BCG. Adv Tuberc Res. 1976; 19:64-126.
15. Moulding T. Chemoprophylaxis of tuberculosis: when is the benefit worth the risk and the cost? Ann Intern Med. 1971;74:761-770.
16. Barrett-Conner E. Nosocomial tuberculosis in physicians: an analysis of direct costs of prevention and disease. Prev Med. 1981;10:69-76.
17. Greenberg PD, Lax KG, Schechter CB. Tuberculosis in house staff: a decision analysis comparing the tuberculin screening strategy with BCG vaccination. Am Rev Respir Dis. 1991;143:490-495.
18. Taylor WC, Aronson MD, DelBanco TL. Should young adults with a positive tuberculin test take isoniazid? Ann Intern Med. 1981;94:808-813.
19. Rose DN, Schechter CB, Fahs MC, Silver AL. Tuberculosis prevention: cost-effectiveness analysis of isoniazid chemoprophylaxis. Am J Prev Med. 1988;4:102-109.
20. Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Morb Mortal Wkly Rep. 1992;41(suppl RR-17):1-13.
21. Centers for Disease Control and Prevention, Division of Tuberculosis Elimination. Tuberculosis Program Management Report: Case Register and Contact Follow-up for 1992. Atlanta, Ga: US Dept of Health and Human Services; 1993. Form CDC 72.15.
22. Centers for Disease Control and Prevention, Division of Tuberculosis Elimination. Tuberculosis Management Report: Completion of Preventive Therapy for 1991. Atlanta, Ga: US Dept of Health and Human Services; 1992. Form CDC 72.21.
23. US Bureau of the Census. Statistical Abstract of the United States 1993. 113th ed. Washington, DC: US Bureau of the Census; 1993.
24. US Immigration and Naturalization Service, Statistics Division. Immigrants Admitted by Country of Birth and Major Category of Admission: Fiscal Years 1991 and 1992. Washington, DC: US Immigration and Naturalization Service; 1994.
25. World Health Organization, Expanded Programme on Immunization. Information System: Summary for the WHO Western Pacific Region, South East Asian Region, European Region. Geneva, Switzerland: World Health Organization; 1993.
26. World Health Organization, Expanded Programme on Immunization. Information System: Summary for the WHO American Region, Eastern Mediterranean Region, African Region. Geneva, Switzerland: World Health Organization; 1993.
27. Centers for Disease Control and Prevention. National HIV Serosurveillance Summary: Results Through 1992. Atlanta, Ga: US Dept of Health and Human Services; 1994;3.
28. Book of the Year 1993. Nations of the world-United States. In: Encyclopedia Britannica. 15th ed. Chicago, Ill: Encyclopedia Britannica; 1993:741.
29. Stokey E, Zeckhauser R. A Primer for Policy Analysis. New York, NY: WW Norton & Co Inc; 1978.
30. Jain RK. A semi-Markov model for average length of stay in transient states and its application. Comput Biomed Res. 1989;22:209-214.
31. Busillo CP, Lessnau KD, Soumakis S, et al. Multidrug resistant Mycobacterium tuberculosis in patients with human immunodeficiency virus infection. Chest. 1992;102:797-801.
32. Bellin E. Failure of tuberculosis control: a prescription for change. JAMA. 1994;271:708-709.
33. Rieder HL, Kelly GD, Bloch AB, Cauthen GM, Snider DE. Tuberculosis diagnosed at death in the United States. Chest. 1991;100:678-681.
34. Seaholm SK, Ackerman E, Wu SC. Latin hypercube sampling and the sensitivity analysis of a Monte Carlo epidemic model. Int J Biomed Comput. 1988;23:97-112.
35. Blower SM, McLean AR, Porco TC, et al. The intrinsic transmission dynamics of tuberculosis epidemics. Nature Med. 1995;1:815-821.
36. Blower SM, Dowlatabadi H. Sensitivity and uncertainty analysis of complex models of disease transmission: an HIV model, as an example. Int Stat Rev. 1994;62:229-243.
37. Salomon N, Perlman DC, Friedmann P, Kreiswirth BN, Mildvan D. Predictors and outcomes of multidrug-resistant tuberculosis. Clin Infect Dis. 1995;21:1245-1252.
38. Centers for Disease Control. A strategic plan for the elimination of tuberculosis in the United States. MMWR Morb Mortal Wkly Rep. 1989;38 (suppl S-3):1-25.
39. Blower SM, Small PM, Hopewell PC. Control strategíes for tuberculosis epidemics: new models for old problems. Science. 1996;273:497-500.
40. Weinstein MC, Coxson PG, Williams LW, Pass TM, Stason WB, Goldman L. Forecasting coronary heart disease incidence, mortality, and cost: the coronary heart disease policy model. Am J Public Health. 1987;77:1417-1426.
41. Karon JM, Buehler JW, Byers RH, et al. Projections of the number of persons diagnosed with AIDS and the number of immunosuppressed HIV-infected persons-United States, 1992-1994. MMWR Morb Mortal Wkly Rep. 1992;41(suppl RR-18):1-29.
42. American Thoracic Society. Control of tuberculosis in the United States. Am Rev Respir Dis. 1992;146:1623-1633.
43. Burwen D, Bloch A, Griffin I, Stern H, Onorato I. National trends in AIDS cases with tuberculosis (TB) and TB cases with AIDS. In: Proceedings of the International Conference on AIDS, June 6-11, 1993. Abstract PO-B07-1166.
44. Graham NM, Chaisson RE. Tuberculosis and HIV infection: epidemiology, pathogenesis, and clinical aspects. Ann Allergy. 1993;71:421-428.
45. Carter EJ. The essentials of a tuberculosis elimination program. R I Med. 1992;75:449-450.
46. Centers for Disease Control. Screening for tuberculosis and tuberculous infections in high risk populations - recommendations of the Advisory Committee for Elimination of Tuberculosis. MMWR Morb Mortal Wkly Rep. 1990;39(suppl RR-8):1-7.
47. Centers for Disease Control and Prevention. Mortality attributable to HIV infection/AIDS among persons 25-44 years - United States, 1990, 1991. MMWR Morb Mortal Wkly Rep. 1993;42:481-485.
48. Braun MM, Cote TR, Rabkin CS. Trends in death with tuberculosis during the AIDS era. JAMA. 1993;269:2865-2868.
49. Centers for Disease Control and Prevention. Tuberculosis Statistics in the United State, 1991. Atlanta, Ga: US Dept of Health and Human Services; 1993:14.
50. Hart PD, Sutherland I. BCG and Vole bacillus vaccines in the prevention of tuberculosis in adolescence and early adult life. BMJ. 1977;2:293-295.
51. Dooley SW, Villarino ME, Lawrence M, et al. Nosocomial transmission of tuberculosis in a hospital unit for HIV-infected patients. JAMA. 1992; 267:2632-2635.
52. Daley CL, Small PM, Schecter GF, et al. An outbreak of tuberculosis with accelerated progression among persons infected with the human immunodeficiency virus: an analysis using restriction-fragment-length polymorphisms. N Engl J Med. 1992;326:231-235.
53. Comstock GW, Woolpert SF, Livesay VT. Tuberculosis studies in Muscogee County, Georgia: twenty-year evaluation of a community trial of BCG vaccination. Public Health Rep. 1976;91:276-280.
54. Selwyn PA, Hartel D, Lewis VA, et al. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med. 1989;320:545-550.
55. Alland D, Kalkut GE, Moss AR, et al. Transmission of tuberculosis in New York City: an analysis by DNA fingerprinting and conventional epidemiologic methods. N Engl J Med. 1994;330;1710-1716.
56. Small PM, Hopewell PC, Singh SP, et al. The epidemiology of tuberculosis in San Francisco. N Engl J Med. 1994;330:1703-1709.
57. Hobby GL, Johnson PM, Boytar-Papirnyk V. Primary drug resistance: a continuing study of drug resistance in a veteran population within the United States. Am Rev Respir Dis. 1974;110:95-98.
58. Goble M, Iseman MD, Madsen LA, Waite D, Ackerson L, Horsburgh CR Jr. Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. N Engl J Med. 1993;328: 527-532.
59. Fischl MA, Daikos GL, Uttamchandani RB, et al. Clinical presentation and outcome of patients with HIV infection and tuberculosis caused by multiple-drug-resistant bacilli. Ann Intern Med. 1992; 117:184-190.
60. Small PM, Schecter GF, Goodman PC, Sande MA, Chassion RE, Hopewell PC. Treatment of tuberculosis in patients with advanced human immunodeficiency virus infection. N Engl J Med. 1991; 324:289-294.
61. Dutt AK, Moers D, Stead WW. Short-course chemotherapy for tuberculosis with mainly twice-weekly isoniazid and rifampin: community physicians' seven-year experience with mainly outpatients. Am J Med. 1984;77:233-242.
62. Ferebee SH. Controlled chemoprophylaxis trials in tuberculosis: a general review. Adv Tuberc Res. 1970;17:28-106.
63. Selwyn PA, Sckell BM, Alcabes: P, Friedland GH, Klein RS, Schoenbaum EE. High risk of active tuberculosis in HIV-infected drug users with cutaneous anergy. JAMA. 1992;268:504-509.
64. Cohn DL, Catlin BJ, Peterson KL, Judson FN, Sbarbaro JA. A 62-dose, 6-month therapy for pulmonary and extrapulmonary tuberculosis: a twice-weekly, directly observed, and cost-effective regimen. Ann Intern Med. 1990;112:407-415.
65. Rose DN, Schechter CB, Silver AL. The age threshold for isoniazid chemoprophylaxis: a decision analysis for low-risk tuberculin reactors. JAMA. 1986;256:2709-2713.
66. Kopanoff DE, Snider DE, Caras GJ. Isoniazid-related hepatitis: a U.S. Public Health Service cooperative surveillance study. Am Rev Respir Dis. 1978;117:991-1001.
67. Rose DN, Schechter CB, Sacks HS. Preventive medicine for HIV-infected patients: an analysis of isoniazid prophylaxis for tuberculin reactors and for anergic patients. J Gen Intern Med. 1992;7:589-594.
68. Colditz GA, Brewer TF, Berkey CS, et al. Efficacy of BCG vaccine in the prevention of tuberculosis: meta-analysis of the published literature. JAMA. 1994;271:698-702.
69. Lotte A, Wasz-Hockert O, Poisson N, et al. Second IUATLD study on complications induced by intradermal BCG-vaccination. Bull Int Union Tuberc Lung Dis. 1988;63:47-59.
70. Besnard M, Sauvion S, Offredo C, et al. Bacillus Calmette-Guérin infection after vaccination of human immunodeficiency virus-infected children. Pediatr Infect Dis J. 1993;12:993-997.